ライフサイエンスコーパス: viremia

1 tients (147 CMV disease and 135 asymptomatic viremia).

2 pithelial cells in the absence of detectable viremia.

3 a prolonged period of intermittent low-level viremia.

4 h an epidemic ZIKV, and completely prevented viremia.

5 IRF4(hi) subsets than did animals with high viremia.

6 eactive airway disease than patients without viremia.

7 ient developed CMV-T cell responses post-CMV viremia.

8 experienced full suppression of HIV-1 plasma viremia.

9 ues, especially in the setting of persisting viremia.

10 in the mesenteric lymph node correlated with viremia.

11 ficantly with incidence of posttransplant BK viremia.

12 ) were more likely to develop persistent EBV viremia.

13 ion of immune suppression at the onset of BK viremia.

14 between macaques that exhibited high or low viremia.

15 to screen individuals on ART for detectable viremia.

16 ficant subset of patients may have recurrent viremia.

17 patients with SVRs, but not in patients with viremia.

18 tomegalovirus and BK and 2 others EBV and BK viremia.

19 mablast frequency negatively correlated with viremia.

20 , which may be driven partly by maternal HIV viremia.

21 of minimizing immunosuppression to treat BK viremia.

22 the source of virus resulting in viruria and viremia.

23 igh viremia, but not in those with very high viremia.

24 infection when administered at the onset of viremia.

25 positively correlated with decreased plasma viremia.

26 ) do not develop AIDS despite high levels of viremia.

27 V-infected macaques contribute to control of viremia.

28 rals in compensated cirrhosis with low-level viremia.

29 ers did not recover after resolution of peak viremia.

30 documented HHV-6 reactivation and persistent viremia.

31 positively with both acute-phase and chronic viremia.

32 l immunosuppression that contributes to high viremia.

33 rvix were negatively correlated with chronic viremia.

34 postpartum than women who failed to control viremia.

35 of the clinical manifestations or on dengue viremia.

36 which can predict risk of progression to CMV viremia.

37 urines from patients without concomitant BK-viremia.

38 population less efficient in controlling HIV viremia.

39 were prospectively monitored for subsequent viremia.

40 all signs of Ebola virus disease, including viremia.

41 loss of these responses eventually leads to viremia.

42 y appears to achieve complete suppression of viremia.

43 e earlier than in the group with viruria and viremia.

44 y" cells, and/or significant polyomavirus BK viremia.

45 ne in response to chronic Epstein-Barr virus viremia.

46 r HIV subjects with undetectable HCMV plasma viremia.

47 lly HIV-infected individuals with detectable viremia.

48 ad 10-year outcomes similar to those without viremia.

49 tinfection and if this translated to reduced viremia.

50 with patients with prolonged episodes of BK viremia.

51 rugs that are used in combination to control viremia.

52 ember 2013; 32 (32%) tested positive for CMV viremia.

53 Of these 12 patients with late recurrent viremia, 11 had the same HCV genotype/subtype at baselin

54 One patient had HBV viremia 16 months post-LT without detectable HBsAg.

55 (cystitis) (34.9% vs 25.2%), cytomegalovirus viremia (17.8% vs 24.2%), flu-like syndrome (11.6% vs 14

56 nput cells/mouse) experienced very low level viremia (201 copies/mL); sequence confirmation was unsuc

57 From the 16 urines collected during BK viremia, 43.8% were PV-Haufen-positive, and 56.2% were n

58 4+ T cells from PrEP Participant B developed viremia (50 million input cells/surviving mouse), but on

59 like syndrome (11.6% vs 14.1%), polyoma (BK) viremia (8.2% vs 11.1%), and herpes simplex infections (

60 -induced neutralizing activity that prevents viremia after acute infection.

61 that would typically cause rebound in plasma viremia after antiretroviral therapy cessation.

62 ntiretroviral therapy (ART) can fuel rebound viremia after ART interruption and is a central obstacle

63 th both the peak and area under the curve of viremia after depletion.

64 nd nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutr

65 ed by protective HLA alleles, but control of viremia also occurs in the presence of selected CTL esca

66 ve and specific method for monitoring plasma viremia among adults and children on ART at the WHO-reco

67 lant BK viruria including 61 with additional viremia and 22 with nephropathy.

68 ter minimization of immunosuppression for BK viremia and after no intervention for JC viruria.

69 ssion significantly reduced cell-free plasma viremia and also delayed MoMLV-induced disease.

70 The presence of DENV viremia and appearance of IgM during the febrile phase o

71 though previous studies have implicated high viremia and associated immune activation as potential dr

72 omarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pa

73 s study, we sought to compare the quantified viremia and clinical presentation of patients infected w

74 ew marker of response to ART when effects on viremia and clinical response are not met.

75 st was used to compare the proportion of CMV viremia and CMV retinitis in patients transplanted betwe

76 viral entry, and treatment with 25HC reduced viremia and conferred protection against ZIKV in mice an

77 ve examined the correlation between maternal viremia and congenital HCMV infection.

78 loss of early control of virus replication, viremia and fatal Ebola virus disease (EVD).

79 idians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulat

80 8 levels were correlated with detectable HIV viremia and inversely with CD4 count (p<0.0001), consist

81 Little is known about RV viremia and its value as a diagnostic indicator in perso

82 14 postinfection had a significant effect on viremia and mortality, resulting in 100% survival of inf

83 Efficient suppression of HBV viremia and necroinflammation as a result of nucleos(t)i

84 ples from four HIV-infected donors (one with viremia and not on ART and three with viremia suppressed

85 sons, active HIV replication correlated with viremia and occurred in CD4 T cells expressing T follicu

86 mera-infected marmosets exhibited consistent viremia and one showed transient viremia during the cour

87 The ability of IFN-alpha14 to reduce both viremia and proviral loads in vivo suggests that it has

88 erapy allows macaques to effectively control viremia and reconstitute their immune systems without a

89 h period and compare this to the rate of CMV viremia and retinitis in the 4 years prior.

90 indirect effects of CMV, possible impact of viremia and risk factors for CMV infection in pediatric

91 fts from HCMV-positive donors independent of viremia and serostatus.

92 LA class I alleles exhibit better control of viremia and slower disease progression.

93 d and robust immunity that protected against viremia and telemetrically monitored fever.

94 ody correlated temporally with resolution of viremia and termination of virus shedding in oropharynge

95 e multicenter data comparing the kinetics of viremia and toxicities following preemptive treatment wi

96 frequency positively correlated with plasma viremia and unvaccinated macaques had increased plasma c

97 ighly sensitive and specific, but periods of viremia and viruria are brief, limiting the utility of Z

98 man primates characterized by high levels of viremia and virus titers in peripheral organs.

99 test was only seen in some patients with BK viremia and was not associated with hemorrhagic cystitis

100 RV-C infections were highly associated with viremia and were usually the only respiratory pathogen i

101 need to improve methods used to monitor HDV viremia and will be instrumental in achieving that goal.

102 to enhance viral uptake, leading to enhanced viremia and worsening of disease.

103 ingly contradictory observations on residual viremia and, with relatively few parameters, recapitulat

104 Evaluation of safety, vaccine viremia, and neutralizing antibody response after each d

105 as analyzed as a function of age, sex, Ebola viremia, and Plasmodium species parasitemia.

106 acterized by persistent high-level shedding, viremia, and seroconversion.

107 lay between HBV serological status, level of viremia, and the immunosuppressive potency of the drug(s

108 lted in increased morbidity-including fever, viremia, and viral loads in spinal cord and testes-and i

109 s was consistently observed, with occasional viremia, and virus was isolated from tonsils, gut mucosa

110 Cytomegalovirus viremia (any and high-level) was more frequent among rec

111 Viremia appears to occur frequently, particularly postpa

112 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (n

113 High levels of viremia as well as immune activation and dysfunction hav

114 of the NHP species studied, the magnitude of viremia, as measured by area under the curve, during the

115 cleared were among the 15 with undetectable viremia at 12 months, making that time point a strong pr

116 te-phase production of MCP-1 correlated with viremia at 3 months postinfection in both nonprogressive

117 nfection, correlated positively with chronic viremia at 3 months postinfection.

118 Maternal viremia at amniocentesis is associated with a 3-fold gre

119 ollers have the striking ability to maintain viremia at extremely low or undetectable levels without

120 Background: HIV-1-controllers maintain HIV-1 viremia at low levels (normally <2000 HIV-RNA copies/mL)

121 HIV-1-controllers maintain HIV-1 viremia at low levels (normally <2000 HIV-RNA copies/mL)

122 for an estimated 52.0% of patients with DENV viremia at presentation.

123 LT recipients with undetectable or low-level viremia at time of LT.

124 to achieve SVR in patients with undetectable viremia at week 1, but would be suboptimal in general.

125 However, even if the portion of viremia attributable to viral replication is significant

126 In addition to the effect on plasma viremia, bnAb administration resulted in significantly r

127 specific reduction of MoMLV cell-free plasma viremia but not the number of infected hematopoietic cel

128 urther study in patients with medium to high viremia, but not in those with very high viremia.

129 Interestingly, viral load and tissue viremia, but not intermittent viral blips, were associat

130 of macaques with a high ZIKV dose results in viremia, but that transmission risk from saliva of infec

131 n NAb titer decreased the risk of developing viremia by 56%.

132 1074-sensitive and showed a rapid decline in viremia by a mean of 1.52 log10 copies/ml.

133 Suppression of viremia by antiretroviral therapy (ART) leads to quantit

134 5 transplant recipients with and without CMV viremia by using a microarray chip covering 847 hsa-miRN

135 There is concern that even low levels of viremia can result in CZS, meaning an effective vaccine

136 retroviral therapy (ART) correlated with HIV viremia, CD4(+) T-cell counts, and immune activation mar

137 ow a reduction in the number of days of ZIKV viremia compared to naive macaques and that the previous

138 , although with significantly delayed plasma viremia compared to the control animals.

139 hat predicted protection from subsequent CMV viremia (concordance index 0.88 [SE, 0.087]).

140 NKG2D, and IL-18Ralpha were associated with viremia control, as was Ab-dependent cytotoxic function.

141 (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that i

142 to build the following cumulative measures: viremia copy-years, CD4-years, and VACS Index score-year

143 ed horses became viremic after 1 or 2 wk and viremia could be detected in two horses for several week

144 as an avidity index of <30%, followed by HCV viremia detection) had an MDRI of 147 days (95% confiden

145 after treatment of the first episode of CMV viremia/disease.

146 drug resistance should be suspected when CMV viremia (DNAemia or antigenemia) fails to improve or con

147 virus that was detected as persistent plasma viremia during cART in an HIV-1-infected patient who had

148 row plasmablasts and plasma cells to control viremia during chronic infection.

149 e 669 patients (58%) had at least 1 positive viremia during follow-up.Epstein-Barr virus D+/R- patien

150 consistent viremia and one showed transient viremia during the course of follow-up detection.

151 was then correlated with the incidence of BK viremia during the first year posttransplantation.

152 g a second agent in patients with persistent viremia during treatment, and the effectiveness of antiv

153 F) viral rebound or sustained plasma and CSF viremia during treatment.

154 chastic models to gain insight into residual viremia dynamics in HIV-infected patients.

155 Among 329 patients, we observed 399 viremia episodes in 223 (68%) patients.

156 We studied viremia episodes with cytomegalovirus (CMV), Epstein-Bar

157 ; 112 (34%) patients had multiple concurrent viremia events.

158 Patients with only low level BK viremia expressed low frequencies of polyfunctional T ce

159 s in tonsils and Peyer's patches (explaining viremia), extending previous studies of poliovirus patho

160 cinated sheep, as evidenced by prevention of viremia, fever and absence of RVFV-associated histopatho

161 ous CCR5 Delta32 donor has had no detectable viremia for 9 years after HAART cessation.

162 Two children had uncontrolled viremia for fifteen and thirty months, respectively, bef

163 nths of age and showed suppression of plasma viremia for seven to nine years.

164 regimens could conceivably suppress rebound viremia from persistent HIV reservoirs.

165 Viremia gradually climbs during gestation but sometimes

166 first episode of CMV disease or asymptomatic viremia (>/=1000 IU/mL) requiring treatment were identif

167 ndergoing immunosuppression reduction for BK viremia had 10-year outcomes similar to those without vi

168 Mice with high levels of viremia had HBV-infected liver progenitor cells.

169 oth patients with either HBsAg positivity or viremia had recurrent hepatocellular carcinoma diagnosed

170 The remaining 5 patients with late recurrent viremia had virologic relapse in which the HCV present a

171 ng strain had a lower risk of developing BKV viremia (hazard ratio [HR], 0.44; 95% confidence interva

172 us, despite their partial ability to control viremia, HIV-specific CD8(+)T cell responses are insuffi

173 gnificantly increased the risk of developing viremia (HR, 2.27; 95% CI, 1.06 to 4.88; P=0.04).

174 Older PHIVY were at increased risk of viremia, immunosuppression, CDC-B events, CDC-C events,

175 with the ability of the antibodies to reduce viremia in a mouse model.

176 (+) lymphocytes resulted in increased plasma viremia in all animals and that repopulation of CD8(+) T

177 rhesus macaques results in detectable plasma viremia in all animals by 2 days post-exposure; virus re

178 e HIV-1 envelope glycoprotein (Env) suppress viremia in animal models of HIV-1 and humans.

179 eeks of infection correlated positively with viremia in chronic infection.

180 vent infection in animal models and suppress viremia in HIV-1-infected individuals.

181 ontribution of viral replication to residual viremia in patients on ART may be non-negligible.

182 under 2 clinical trials and leads to reduced viremia in patients.

183 accine to prevent or significantly attenuate viremia in pregnant women who are residents of or travel

184 f the study, 3 weeks after the resolution of viremia in the blood.

185 hat maintained low to undetectable levels of viremia in the chronic phase of infection.

186 neutralizers typically are unable to reduce viremia in the same individuals from whom they are isola

187 lization in vitro and a moderate decrease of viremia in vivo IMPORTANCE: Antibodies can protect from

188 avel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners

189 1 infection to undetectable levels of plasma viremia, integrated latent HIV-1 genomes that encode rep

190 The source of this viremia is an area of debate: does it derive primarily f

191 ity, the detection window of RT-PCR for Zika viremia is only about one week after symptom onset.

192 potential donor per year), if the absence of viremia is required for transplantation.

193 L; P = .01), a 0.76 log10 lower longitudinal viremia level (P = .01), and slower progression to a CD4

194 the time to CD4(+) T-cell count decline and viremia level after infection and the potential for vacc

195 n a novel lethal mouse model, it lowered the viremia level and the virus load in organs and normalize

196 In contrast to prior reports, the persistent viremia level continues to slowly decline during years 4

197 , commenced 4 days after infection, when the viremia level had reached 4 log10 virus particles/mL, re

198 The viremia level was elevated 10-fold in EBOV-C05-infected

199 rated genome-wide genotype, gene expression, viremia level, and weight gain data to identify genetic

200 %-69% and 90%-84% of cases, respectively, as viremia levels declined, while anti-DENV IgM ELISA detec

201 long-lived humoral immune responses, despite viremia levels of up to 6.44 log10 copies per mL of seru

202 ssion of GBP5, GBP6, CCHCR1 and CMPK2 affect viremia levels or weight gain in response to PRRSV infec

203 d with A1-160Q or A1-160M viruses had higher viremia levels than those infected with A1-160K.

204 ing HIV prevalence and the prevalence of HIV viremia (linear regression coefficient per 1-percentage-

205 onstructural protein 1 (NS1) rapid test, and viremia magnitude were all independently associated with

206 ry pathogen identified, suggesting that RV-C viremia may be an important diagnostic indicator in pedi

207 In women with VEs, peak viremia (median, 3.79 log10 copies/mL) was linearly rela

208 here monocytes/macrophages contribute to CNS viremia, neuroinflammation, and increased mortality.

209 t allogeneic HSCT; 13 patients (46%) had CMV viremia, not a statistically significant increase (P = .

210 After vaccination, rVSV viremia occurred frequently but was transient.

211 e occurred in 13 (33%) of 39 and relapses of viremia occurred in 31%.

212 zing serostatus had the greatest risk for BK viremia (odds ratio, 4.9; 95% confidence interval, 1.7-1

213 led for the disease with a consistent plasma viremia of <200 copies/mL (mean CD4(+)-cell count, 475.1

214 ally infected untreated subjects with plasma viremia of <3,000 RNA copies/ml over 17 to 179 weeks.

215 ollers, defined as those with episodes of BK viremia of 3 months or less, had an 11-fold increase in

216 into rhesus monkeys did not result in either viremia or apparent clinical symptoms, although DTMUV-sp

217 The primary outcome was recurrence of CMV viremia or disease within 6 months of treatment disconti

218 Expression was independent of HCMV viremia or IgG serostatus.

219 blood samples obtained from individuals with viremia or individuals on long-term suppressive antiretr

220 The effect of polyomavirus reactivation (BK viremia or JC viruria) on antibodies to kidney-specific

221 t risk factor for posttransplant viruria and viremia (OR, 4.52; CI, 2.33-8.77; P < 0.0001) and nephro

222 tly elevated in individuals with high plasma viremia (P < 0.0001) and are positively correlated with

223 , male Breg frequencies correlated with peak viremia (p = 0.0071).

224 ot males also correlated with decreased peak viremia (p = 0.028).

225 V nephropathy than in those with viruria and viremia (P = 0.045).

226 nvestigated the prevalence of late recurrent viremia (patients with sustained virologic response 12 w

227 nce interval, 1.88-157.87; P = 0.012), while viremia per se did not worsen LT outcomes, such as the i

228 In these persons, HHpgV-1 viremia persisted for a median of at least 4538 days and

229 infected animals with persistent circulating viremia presented characteristics typical of viral hepat

230 epositories for having varying degrees of BK viremia (range, 0-1.0 x 10 copies/mL), hemorrhagic cysti

231 The observed cytomegalovirus (CMV) viremia rate for patients at risk was low (15%), as were

232 15.2%-64.6%), significantly higher than the viremia rate of 0.93% (95% CI, .11%-3.34%) in nonexposed

233 d suppression of viral replication with ART, viremia rebounds rapidly after treatment interruption.

234 Thirteen individuals with viremia received the highest dose of 30 mg/kg 10-1074.

235 s of HBV-specific T cells caused progressive viremia reduction within 12 days of treatment in animals

236 detection rate of HIV-infected persons with viremia (regardless of their awareness status) was 0.7 p

237 izing activity (D+) had elevated risk for BK viremia, regardless of recipient serostatus (D+ versus D

238 with haplotype-matched hepatocytes, whereas viremia remained stable in mice receiving irrelevant T c

239 g therapy or those who spontaneously control viremia remains an obstacle to definitive treatment.

240 s were detected in levels of residual plasma viremia, replication-competent reservoirs, proviral DNA,

241 The first episode of CMV viremia requiring antiviral therapy was assessed in 282

242 ne responses correlated with the kinetics of viremia resolution, the CD8 T-cell response was of surpr

243 Indeed, long after viremia resolution, there was persistent viral RNA detec

244 ibody and T-cell response to HCV NS3 in this viremia-resolved marmoset was boosted by rechallenging,

245 Viremia results demonstrated that EBOTAb resulted in a d

246 ation led to HIV-1 reservoir reduction after viremia resuppression, as indicated by the quantity of H

247 virus in both regular samples and simulated viremia samples.

248 reservation techniques, lower CNI dosing, BK viremia screening) may have had.

249 cipient serostatus and the development of BK viremia, specific risk factors for BKV-related complicat

250 inal fluid for months after the clearance of viremia suggest the ability of ZIKV to establish persist

251 e with viremia and not on ART and three with viremia suppressed on ART) revealed that an average of 7

252 irus evolution in any of the 8 children with viremia suppression on ART.

253 teen and thirty months, respectively, before viremia suppression, and served as positive controls for

254 ed with nsp1beta mutants had lower levels of viremia than did WT virus-infected pigs.

255 all patients, hospitalized cases had higher viremia than those who did not require hospitalization (

256 Patients with severe disease had higher viremia than those with moderate disease.

257 nd implement screening measures for AIV H5N1 viremia that allows for rapid response to this potential

258 ads to a significant enhancement of Dengue-2 viremia that is accompanied by neutropenia, lympocytosis

259 = 0.005); and a gene known to relate to HIV viremia, THBS1 (P = 0.003).

260 s in tonsils and Peyer's patches (explaining viremia), thereby supplementing historical reconstructio

261 We observed that ART suppressed viremia to <60 copies/ml of plasma in 10 of 12 animals a

262 gins in the respiratory tract and spreads by viremia to internal organs.

263 iretroviral therapy (cART) suppresses plasma viremia to undetectable levels that rebound upon cART tr

264 s was consistently observed, with occasional viremia; tonsil, mesentery lymph nodes, and intestinal m

265 aneous clearance was defined as undetectable viremia twice at least 6-months apart.

266 men enrolled in U.S. cohort studies for HEV viremia using a high-throughput nucleic acid testing (NA

267 from FMD clinical signs and did not develop viremia, virus shedding or antibodies against FMDV nonst

268 type I IFN receptor in mice caused apparent viremia, viscerotropic disease, and mortality, indicatin

269 e from the onset of symptoms to clearance of viremia was 17.5 days.

270 Prevalence of HEV viremia was 3 of 2,606 and 0 of 313 in tested plasma sam

271 Of 39 134 recruited blood donors, DENV-4 viremia was confirmed in 0.51% of donations from subject

272 Viremia was consistently detected for 5 to 54 weeks of f

273 armoset was boosted by rechallenging, but no viremia was detected during 57 weeks of follow-up.

274 Vaccine viremia was detected within 3 days in 123 of the 130 par

275 Neither dengue nor Zika viremia was higher in patients with prior DENV infection

276 The incidence of late recurrent viremia was low.

277 Quantifiable viremia was lower in ZIKV infections compared with CHIKV

278 Transient rVSV viremia was noted in all the vaccine recipients after do

279 than controls, but a trend for higher acute viremia was observed in the DM+VLP group, likely due to

280 and soluble CD40 ligand (sCD40L) and chronic viremia was observed only for the nonprogressive infecti

281 and 14), and saliva (until day 42), but the viremia was rapidly controlled.

282 Remarkably, the incidence of posttransplant viremia was reduced among cases with high pretransplant

283 Assessment of CMV viremia was restricted to symptomatic cases in the retro

284 both comparisons), and for each virus, mean viremia was significantly lower in coinfections than in

285 y (ART)-naive individuals were enrolled, and viremia was suppressed by ART prior to delivery of 4 dos

286 levels without ART, and in individuals whose viremia was suppressed by ART.

287 sure changes, episodes of intermittent HIV-1 viremia were infrequent.

288 The rates of adverse events and viremia were lower after the second dose than after the

289 Acute and post-cART levels of viremia were similar, however, the levels of inflammator

290 enotype and 12-month postpartum undetectable viremia were the best predictors for viral decline and s

291 om respiratory specimens (48.8%), almost all viremias were RV-C (98.2%).

292 previously exposed to DENV exhibited higher viremia when exposed to a subsequent, heterologous dengu

293 munized animals had significantly lower peak viremia which inversely correlated with prechallenge SIV

294 l, could be detected early after start of BK viremia, which would provide insight into the mechanism

295 ot observed in every patient with detectable viremia who received preemptive antiviral therapy, sugge

296 Four patients developed CMV viremia with clearance by 1.2 months, which correlated w

297 Viremia with CMV, EBV, HHV-6, HSV-1, HSV-2, and VZV was

298 STATEMENT Despite successful suppression of viremia with increased longevity in the era of combined

299 ecipients but does not lead to resolution of viremia without T-cell immune-reconstitution.

300 y transmit for months after the clearance of viremia, ZIKV must establish infection in the seminifero